Cardiometabolic diseases

Optimizing cardiometabolic disease management together.

Find more products Contact us
Cardiometabolic disease management illustration - This illustration shows a hospital and remote care setting where cardiac patients are diagnosed and treated

Optimizing cardiometabolic disease management together

Our commitment

We discover and develop novel, high-quality, accurate assays for innovative cardiometabolic biomarkers

As the leader in in vitro diagnostics, we discover and develop novel, high-quality, accurate assays for innovative biomarkers, through:

  • Continuous innovation: We aim to deliver on unmet medical needs to enable excellence in patient-centric decision-making.
  • Connecting solutions: We develop and offer innovative decision support and disease management solutions to optimize patient management across the continuum of care.
  • Creating evidence: We invest in evidence creation to gain new insights that will transform diagnostics and drive further development of CMD guidelines and policies, ultimately supporting improved outcomes for patients.
Disease burden

The impact of cardiometabolic diseases

Cardiometabolic diseases present a major healthcare burden and cardiovascular diseases are a significant cause of premature death;1‑4 18.5 million deaths per year, one-third of all deaths globally.5

Cardiometabolic conditions form a continuum that starts from cardiovascular risk factors, and without intervention, can progress to myocardial infarction, stroke, heart failure, and death.20-22 Due to this high interdependence, they can no longer be treated in isolation. Fragmented care can lead to redundant diagnostic testing and higher healthcare costs.21,28-30

Diagnostic challenges and impact

The importance of diagnostics

Diagnostic tests play a crucial part in healthcare. They account for only a fraction of the total healthcare spending (<2%), while informing ~70% of clinical decisions.6

As the global market leader in in vitro diagnostics, Roche continuously invests in evidence generation on new uses of biomarkers to improve cardiometabolic care and outcomes for patients.9-11 In 2023 alone, we invested CHF 13.2 million in research and development and delivered 6 new platforms, 21 diagnostic tests and 7 digital solutions,12 alongside CMD pipeline acceleration through partnerships and acquisitions.13

With biomarkers and digital solutions, Roche enables earlier diagnosis, reducing time to discharge, and providing information for personalized treatment plans.15,31

Featured products

Improving heart failure outcomes together at every step.

Explore Heart failure
No products found for this filter.
Find more products

Streamlining clinical decision-making in acute coronary syndrome.

Explore Coronary artery disease
No products found for this filter.
Find more products

Benefits of Roche diagnostic and management solutions for cardiometabolic diseases

Continuing innovation

Innovative biomarkers for patient-centric decision-making

Cardiometabolic diseases present a major healthcare burden and cardiovascular diseases are a significant cause of premature death;1-4 18.5 million deaths per year, one-third of all deaths globally.5

At Roche we are the global market leader in in vitro diagnostics for cardiac indications. With continuous investment for the past 30 years, we remain committed to optimizing cardiometabolic (CMD) care, developing and improving diagnostic tests essential in CMD decision-making.7-11

  • Roche has been the pioneer in CVD biomarkers for more than a decade, including high-sensitive Troponin T and NT-proBNP, and is committed to continue bringing even more accurate diagnostics solutions to market.7-11,14
  • We continuously invest in high quality assays with better rule-in rule-out processes, streamlining decision-making by providing rapid access to crucial diagnostic information, reducing the need for stress testing and time to discharge.15-16
  • Roche assays support efficient clinical decision-making across healthcare settings along the patient journey, from risk stratification and early diagnosis of heart attacks and heart failure to monitoring heart failure and patients with chronic artery disease.9-17,19
Connecting solutions

Innovative decision support and disease management solutions

At Roche we develop and offer innovative decision support and disease management solutions to optimize patient management across the cardiac continuum of care.

Addressing unmet needs in cardiometabolic disease (CMD) has direct operational and clinical benefits, as CMDs can lead to unnecessary hospital admissions, overcrowded emergency departments, high bed occupancy and a negative impact on quality of care, with 44%–96% of heart failure care cost attributed to hospitalizations globally.23-27

Cardiometabolic conditions are highly interdependent and can no longer be treated in isolation. They need coordinated care from multidisciplinary teams as fragmented care leads to redundant diagnostic testing and higher costs.21,28-30

Roche empowers healthcare professionals with earlier diagnosis, reducing time to discharge, and providing information for personalized treatment plans by offering biomarkers and solutions used across the continuum of cardiac care.15,22

  • Our validated cobas® h 232 and Elecsys® offering is standardized across the laboratory and at the point of care, providing comparable and reliable results for consistent management wherever a patient receives care.7,32,33
  • Our connected diagnostic solutions and the ability to compare results across diagnostic platforms can help diagnose patients earlier, which is invaluable in preventing disease progression, provides clinical improvements and can influence treatment decisions across the continuum of care.7,31,32,34,35
  • The Roche Healthcare Consulting team can work with healthcare organizations to understand their needs, ensuring that solutions are successfully localized, scaled and integrated in a way that brings maximum benefits to patients and healthcare professionals.36
  • Our Advanced Access DMS platform seamlessly integrates existing stand-alone components like remote patient monitoring and diagnostic insights with HCP’s clinical acumen.
  • With navify® Algorithm Suite, healthcare professionals can easily order the medical algorithms they need from Roche, generating actionable insights to drive personalized healthcare and improve patient care.38
Creating evidence

Continuous evidence generation to transform diagnostics

We invest in evidence creation to gain new insights that will transform diagnostics and drive further development of cardiometabolic disease (CMD) guidelines and policies, ultimately supporting improved outcomes for patients.9-11

  • Through our continued investment into research and development, we have gathered the evidence needed to broaden the range of intended uses of our biomarkers, as with NT-proBNP and cTnT-hs.7,8
  • Our troponin and NT-proBNP assays have been featured in over 3,600 publications, with breakthrough publications over nearly two decades that have helped the scientific community make informed decisions.9-11,39-46
  • We have invested in, co-sponsored or supported valuable evidence generation to aid experts in developing guidelines, leading to better protocols and new policies.9,10,47-49
  • Roche is committed to creating evidence to support the clinical implementation of best practices in cardiometabolic diseases; for example, the impact of STRONG-HF goes beyond the clinical trial and will influence real-world patient care and management.

You might be interested in

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

Contact us

Explore more

References

  1. Timmis A, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41:12-85. 
  2. Savarese G, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118:3272-87. 
  3. Hasani WSR, et al. The global estimate of premature cardiovascular mortality: a systematic review and meta-analysis of age-standardized mortality rate. BMC Public Health. 2023;23:1561.
  4. Roth GA, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736-88.
  5. Our World in Data. Cardiovascular diseases [Internet; cited 2026 July 3]. Available from: https://ourworldindata.org/cardiovascular-diseases?insight=cardiovascular-diseases-are-the-most-common-cause-of-death-worldwide#all-charts. 
  6. Rohr P, et al. The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. PLoS One. 2016;11:e0149856. 
  7. F. Hoffmann-La Roche Ltd. Elecsys ProBNP II Method Sheet. (v3.0). 2020. 
  8. F. Hoffmann-La Roche Ltd. Elecsys Troponin T hs Method Sheet. (v4.0). 2024. 
  9. Mebazaa A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938-52.
  10. Huelsmann M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62:1365-72.
  11. Devereaux PJ, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2017;317:1642-51. 
  12. F. Hoffmann-La Roche Ltd. Annual Report 2023 [Report; cited 2026 July 3]. Available from: https://assets.roche.com/f/176343/x/98b8e2ba9d/ar23e.pdf . 
  13. F. Hoffmann-La Roche Ltd. 2023 results [Report; cited 2026 July 3]. Available from: https://assets.roche.com/f/176343/x/ac48d3ba3b/irp240201-a.pdf. 
  14. ClinicalTrials.gov. Asian diabetes outcomes prevention trial (ADOPT) [Internet; registry identifier NCT04286399; cited 2026 July 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT04286399. 
  15. Twerenbold R, et al. Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. Eur Heart J. 2016;37;3324-32.
  16. Januzzi JL, et al. N-Terminal Pro-B-Type Natriuretic Peptide in the emergency department: The ICON-RELOADED Study. J Am Coll Cardiol. 2018;71:1191-200.
  17. Badertscher P, et al. Effect of Acute Coronary Syndrome Probability on Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin. Clin Chem. 2018;64:515-25.
  18. Stoyanov KM, et al. RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. Eur Heart J Acute Cardio Care. 2020;9:39-51.
  19. Packer M, et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation. 2015;131:54-61.
  20. Chrysant SG. A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention. Hippokratia. 2011;15:7-11.
  21. Manla Y and Almahmeed W. Cardiometabolic Clinics: Is There a Need for a Multidisciplinary Clinic? Front Clin Diabetes Healthc. 2022;3:880468.
  22. Vassiliadis E, et al. Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum. Biomark Insights. 2012;7;45-57.
  23. Lin D and Akincigil A. PDB63 THE IMPACT OF HEART FAILURE ON DIABETES-RELATED HEALTHCARE UTILIZATION AND COSTS IN ADULT PATIENTS WITH TYPE 2 DIABETES. Value in Health. 2019;22:S151.
  24. Asheim A, et al. High ward occupancy, bedspacing, and 60 day mortality for patients with myocardial infarction, stroke, and heart failure. ESC Heart Fail. 2022;9:1884-90.
  25. Robertson J, et al. The health services burden of heart failure: an analysis using linked population health data-sets. BMC Health Serv Res. 2012;12:1-11.
  26. Nair R, et al. Reducing All-cause 30-day Hospital Readmissions for Patients Presenting with Acute Heart Failure Exacerbations: A Quality Improvement Initiative. Cureus. 2020;12:e7420.
  27. Lesyuk W, et al. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord. 2018;18:74.
  28. Glynn LG. Multimorbidity: another key issue for cardiovascular medicine. Lancet. 2009;374:1421-2.
  29. Reiter-Brennan C, et al. Comprehensive Care Models for Cardiometabolic Disease. Curr Cardiol Rep. 2021;23:22.
  30. Bain S, et al. Delivering joined-up care for people with type 2 diabetes: rationale, challenges and examples. Br J Diabetes. 2021;21:89-95.
  31. Pop-Busui R, et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45:1670-90.
  32. F. Hoffmann-La Roche Ltd. Cobas CARDIAC POC NT-proBNP Method Sheet. (v2.0). 2024. 
  33. Schäfer M, et al. Diagnostic Equivalence of an N-terminal Pro-Brain Natriuretic Peptide Point-of-Care Test to the Laboratory Method in Patients With Heart Failure and in Reference Populations. Point of Care. 2010; 9:91-7.
  34. Pelter MN, et al. Remote Monitoring in Cardiovascular Diseases. Cardio Risk Reports. 2023;17:177-184.
  35. Kim Y, et al. Comparative effectiveness of telemonitoring versus usual care for type 2 diabetes: A systematic review and meta-analysis. J Telemed Telecare. 2018;25(10).
  36. F. Hoffmann-La Roche Ltd. Roche Healthcare Consulting [Internet; cited 2026 July 3]. Available from: https://diagnostics.roche.com/sg/en/services/roche-healthcare-consulting.html.
  37. Medixine. More effective treatment and savings in healthcare with remote monitoring of heart diseases – Roche and Medixine to cooperate [Press release; cited 2026 July 3]. Available from: https://medixine.com/roche-and-medixine-to-cooperate/.
  38. Hoffmann-La Roche Ltd. Roche introduces navify Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care. [Internet; cited 2026 July 3]. Available from: https://www.prnewswire.com/news-releases/roche-introduces-navify-algorithm-suite-a-digital-library-of-medical-algorithms-that-enhances-clinical-decision-making-to-optimise-patient-care-301793922.html.
  39. Halvorsen S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J. 2022;43:3826-924.
  40. Januzzi JL, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-7.
  41. Reichlin T, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med. 2012;172:1211-8.
  42. Mueller C, et al. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016;68:76-87.
  43. Zile MR, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016;68:2425-36.
  44. Roffi M, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315.
  45. Yancy CW, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circ. 2017;136:e137-61.
  46. Collet JP, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42:1289-367.
  47. McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44:3627-39.
  48. Maddox TM, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2024;83:1444-88. 
  49. American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S179–S218.